UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013149
Receipt number R000015323
Scientific Title Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with dyslipidemia, compared to ethyl icosapentate
Date of disclosure of the study information 2014/02/13
Last modified on 2018/08/18 09:03:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with dyslipidemia, compared to ethyl icosapentate

Acronym

Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with

Scientific Title

Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with dyslipidemia, compared to ethyl icosapentate

Scientific Title:Acronym

Elucidation of the effect of Omega-3-Acid ethyl esters for CKD patients with

Region

Japan


Condition

Condition

CKD patients with dyslipidemia

Classification by specialty

Medicine in general Nephrology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Examine the effect of omega 3 fatty acids, compared to ethyl icosapentate for renal function in CKD patients with dyslipidemia

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

(F) LDL, HDL, (F) LDL / HDL ratio, total cholesterol, triglyceride, proteinuria (urinary albumin), sCr, eGFR, urinary L-FABP at 0, 3, and 6 months after starting of treatment

Key secondary outcomes

QOL questionnaire, Quadrant blood fatty acid (EPA / AA ratio, DHA / AA ratio), Oxidized LDL, high-sensitivity CRP, urinary 8-OHDG, ADMA


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

switch to omega 3 fatty acids

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) chronic kidney disease patients with dyslipidemia
2) patients under the medical treatment with Epadel
3) patient who is competent to understand the aim of this study and agree on it

Key exclusion criteria

1) Patients who are bleeding
2) Past medical history of hypersensitivity to Lotriga
3) Judged as ineligible by physicians

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiko Tomino

Organization

Juntendo University Faculty of Medicine

Division name

Department of Internal Medicine, Division of Nephrology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-5802-1065

Email

yasu@juntendo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hitoshi Suzuki

Organization

Juntendo University Faculty of Medicine

Division name

Department of Internal Medicine, Division of Nephrology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-5802-1065

Homepage URL


Email

shitoshi@juntendo.ac.jp


Sponsor or person

Institute

Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

The clinic of Meguro Orthopaedics Surgery and Internal Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 12 Month 24 Day

Date of IRB


Anticipated trial start date

2014 Year 04 Month 14 Day

Last follow-up date

2015 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2017 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2014 Year 02 Month 13 Day

Last modified on

2018 Year 08 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015323


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name